|
Xi appears in Wonner, regardless of price cut, what kind of factors have contributed, in the context of medical reform, lower prices should be a mature market-oriented enterprises the most direct response to market variables. The face of China's health system, in 2009, everything has been rushed out of the Merck sent their own "expert medical reform": February 10, Wonner Yuxi took office, began as Merck China president. 2009 years, many foreign pharmaceutical companies for an extraordinary year for both on the process of healthcare reform plan put all the speculation to the whole industry a lot of uncertainties. In a market full of variables, which can accurately grasp of foreign policy is possible to continue in China 30 years glory. The Wonner Yuxi the tasks are also here. Before coming to China Feng Xi satisfied either Merck French president, France is outside of Merck in the United States one of the most important market. While previously the president of the pharmaceutical market is mature, but Wonner Yuxi is one letter of emerging market experts. Working in Poland, Wonner Yuxi, who led the team greatly improved the performance of Merck, and actively support and promote the local government health system reform. This experience, perhaps a new post China Wonner Yuxi the most powerful support. 2009 12 22, Wonner Yuxi told "Medicine Economic News," an interview that Merck will reduce Drugs The price of measures to support China's medical reform. Merck entered Essential Drugs List (Basic version) star drugs?? "Of Zocor (simvastatin)," will cut prices by 50% to allow more patients to spend more drugs. When other foreign companies are still considering and planning for post-medical reform strategy, the Merck already ringing action that their medical reform policy of China's positive response. From the current market reaction, "the patent expired" and the "pump price for volume" is the industry's intention to cut prices on major speculation Merck, face of the question, "medical reform experts" Wonner Xi said: "Merck's medical reform the Chinese government policy has been very positive, careful study, since the government built the platform, why not stage singing it?" Xi for Wonner, the medical reform this is not strange topic. Only from this first shot, you can see his health care reform has focused on how to locate or fully self-confidence. Had a lot of foreign attention Essential drugs system Once so many were Generic And essential drugs, "zero distance" confront, but the risk is lower prices prompted many foreign companies choose to give up access to essential medicines for primary directory opportunity. The essential medicines list (basic version) is introduced, the industry generally surprised star Merck cholesterol-lowering drug "Zocor" actually entered the essential medicines list. For this choice, many of the industry that do not understand: Why not fought Health Insurance Directory? Why the price is not closely aligned with the RDPAC? Why Essential Medicines List fond of? However, Wonner Yuxi seems that no matter what kind of price reduction factors have contributed to the move, in the context of medical reform, lower prices should be a mature market-oriented enterprises the most direct response to market variables. Present, "Zocor" In China there are two specifications Sell , The access to essential drugs catalog and price reduction of 20 mg 7 installed. Development and Reform Commission in accordance with previously established estimates the maximum retail price of 52.5 yuan, "Zocor" directory into the essential drugs to 25 dollars, fell as much as 52%. Linked to the previous market price cuts and other moves, had to make the world a "patent expiration" and "price reduction and stroke volume" speculation. The Wonner Yuxi that the price reductions and "patent expiration", "price cuts stroke volume," not directly related to price reductions starting point is to let the Chinese real benefits to patients, which are responsive to price reform measures in the government medical and health system reform demands of. Obviously, he has recognized that there is no national policy on the understanding and adaptation, in the Chinese market, foreign companies are likely to lay the discount opportunities. I am an expert from turnstile-gate.com, while we provides the quality product, such as Door Access Controller Manufacturer , China Turnstile Gate, Barrier Turnstile,and more.
Related Articles -
Door Access Controller Manufacturer, China Turnstile Gate,
|
